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Abstract 
Background: Hyperbaric oxygen therapy (HBOT) involves exposing patients to elevated oxygen pressures 
and concentrations for a series of 2 hour sessions. It is commonly used with multiple exposures to treat 
soft tissue degenerative diseases, but a side-effect for some patients is a significant increase in myopia. 
Phase 1: Four subjects receiving 20 or more 2 hour HBOT sessions for soft tissue disease participated in 
this phase of the project. Visual acuities and refractive error corrections were determined before and after 
HBOT sessions at the beginning, midpoint, and end of therapy. No subjects showed significant acuity or 
refractive error changes produced by single HBOT sessions. One subject showed a significant increase in 
myopia over the 20 session course of HBOT. 
Phase 2: Four additional subjects receiving HBOT for soft tissue disease participated in this phase. Visual 
acuity, refractive error correction, A-scan ultrasound, and corneal curvature measurements were made 
before and after selected HBOT sessions. In addition, susceptibility to free radical damage and indicators 
of actual damage were measured by analysis of blood drawn before and after selected sessions. During 
the first half of HBOT therapy, subjects took placebo tablets; during the second half they took antioxidant 
supplements. None of the subjects showed significant effects of single HBOT sessions. However, one 
subject showed a significant increase in myopia over the course of HBOT. No corresponding changes 
were found in the ultrasound, corneal curvature, or blood analysis data. The rate of myopia progression 
was approximately the same for placebo and antioxidant supplement periods. 
Discussion: Two of the 8 subjects experienced significant increases in myopia as a result of HBOT. It is 
likely that this increase was caused by lenticular refractive index changes due to oxidative damage. It was 
not possible to predict which subjects were susceptible to myopia increase nor was evidence of oxidative 
damage found by blood analysis. Antioxidant supplementation did not slow the rate of myopia 
development. 
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ABSTRACT 
Background: Hyperbaric oxygen therapy (HBOT) involves exposing 
patients to elevated oxygen pressures and concentrations for a 
series of 2 hour sessions. It is commonly used with multiple 
exposures to treat soft tissue degenerative diseases, but a side-
effect for some patients is a significant increase in myopia. 
Phase 1: Four subjects receiving 20 or more 2 hour HBOT sessions 
for soft tissue disease participated in this phase of the project. 
Visual acuities and refractive error corrections were determined 
before and after HBOT sessions at the beginning, midpoint, and end 
of therapy. No subjects showed significant acuity or refractive 
error changes produced by single HBOT sessions. One subject showed 
a significant increase in myopia over the 20 session course of HBOT. 
Phase 2: Four additional subjects receiving HBOT for soft tissue 
disease participated in this phase. Visual acuity, refractive error 
correction, A-scan ultrasound, and corneal curvature measurements 
were made before and after selected HBOT sessions. In addition, 
susceptibility to free radical damage and indicators of actual 
damage were measured by analysis of blood drawn before and after 
selected sessions. During the first half of HBOT therapy, subjects 
took placebo tablets; during the second half they took antioxidant 
supplements. None of the subjects showed significant effects of 
single HBOT sessions. However, one subject showed a significant 
increase in myopia over the course of HBOT. No corresponding 
changes were found in the ultrasound, corneal curvature, or blood 
analysis data. The rate of myopia progression was approximately 
the same for placebo and antioxidant supplement periods. 
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l Discussion: Two of the 8 subjects experienced significant 
increases in myopia as a result of HBOT . . It is likely that this 
increase was caused by lenticular refractive index changes due to 
oxidative damage. It was not possible to predict which subjects 
were susceptible to myopia increase nor was evidence of oxidative 
damage found by blood analysis. Antioxidant supplementation did 
not slow the rate of myopia development. 
KEY WORDS 
Hyperbaric, myopia, oxygen, free radical, antioxidant, vitamin, 
cataract, malondialdehyde, vision, eyes. 
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INTRODUCTION 
Hyperbaric oxygen therapy usually involves placing the patient 
in a sealed chamber containing pure oxygen and raising the pressure 
to 2 atmospheres. It is used to treat a number of ischemic 
conditions including carbon monoxide poisoning, osteoradiation 
necrosis, soft tissue radiation necrosis, and necrotizing soft tissue 
infections, e.g., diabetic foot lesions. Typically, a course of 
treatment includes 20 or more 2 hour sessions. 
HBOT has also been used to treat ocular conditions including; 
central retinal artery occlusion, 1-3 toxic amblyopia, 4 and radiation 
j. induced optic neuropathy.s In addition, it has been used 
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experimentally to treat glaucomas and chronic cystoid macular 
edema.? 
Under normal circumstances (i.e., breathing room air at one 
atmosphere of pressure), the hemoglobin in arterial blood is 97% 
saturated with oxygen. The purpose of HBOT is not to oxygenate the 
remaining 3% of hemoglobin but to dissolve oxygen in the blood 
plasma. a The partial pressure of oxygen is dramatically increased 
and this dissolved oxygen is then forced into the tissues as blood 
flows through the capillaries. 
A problem in treating non-healing skin lesions or radiation 
induced soft tissue necrosis is often the underlying capillary bed is 
damaged. This creates localized ischemia which inhibits the healing 
process. HBOT produces higher levels of oxygen in the tissues, 
which stimulates revascularization and aids in tissue repair. 
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Visual Side-Effects of HBOT 
For the body, oxygen is very much a two-edged sword; although 
it is necessary to sustain life, oxygen's damaging effects are well 
known. Many organs such as the eye are quite susceptible to 
toxicity. For example, retinopathy of prematurity is considered to 
be a toxic effect of oxygen. Nuclear cataracts and myopia have also 
been described as potential side-effects of exposure to increased 
oxygen pressure and/or concentration. 
HBOT induced myopia was first reported in 1978 by two 
separate groups. Anderson and Farmer9 studied seven HBOT patients 
ages 51 to 69. Each patient received 40 two hour HBOT treatments, 
(80 hours total) and all experienced increased myopia. Their mean 
spherical equivalent increase was -1.61 diopters (D) with a range of 
-0.50 to -2.50 D. In another study, Lyne 1 o described 26 patients 
(ages 36 to 80 years) who received HBOT for periods ranging from 4 
to 52 weeks. Eighteen of the 26 patients experienced increases in 
myopia of -0.50 to -5.50 D. 
In 1984, Palmquist et al.11 a~lso reported myopic shifts caused 
by HBOT. Twenty-five patients from 23 to 68 years of age were 
followed through 150 to 850 hours of treatment. All 25 experienced 
increases in myopia, (mean increase -3.00 D), but in 23 of the 25 
subjects the increase was not noted until after 100 hours of HBOT. 
Palmquist et aJ.11 were also among the first to report the 
development of cataracts as a side-effect of HBOT. Of the 15 
subjects who had clear lenses at the beginning of HBOT, 7 developed 
nuclear cataracts with sufficient density to reduce acuity. 
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Etiology of Vision Changes Produced by HBOT 
Changes in axial length of the eye, corneal curvature, 
accommodative tonus, lens position, and/or lens power can all 
produce increases in myopia. Axial length changes sufficient to 
explain the degree of myopia increase found in HBOT subjects have 
not been detected, 10,12 nor have changes in keratometric 
findings. 9,1 o, 12 In addition, cycloplegic examinations have been 
used to rule out changes in accommodative tonus as a cause of the 
myopic shifts.1 o These findings suggest that alterations in the 
crystalline lens are responsible for the increase in myopia produced 
by HBOT. 
It is possible that osmotic changes, like those experienced by 
diabetics or patients taking diuretics, could be responsible for the 
lenticular changes, but osmotic effects reverse rapidly when blood 
sugar levels are normalized or medications are withdrawn. 
Conversely, HBOT induced myopia can last up to a year or more after 
the end of therapy, and some subjects never return to baseline 
values.9-12 
The most probable cause of increased myopia in HBOT patients 
is currently believed to be lenticular damage produced by free 
radical oxidative processes that result in an index change and/or a 
· swelling of the lens. According to this theory raising the oxygen 
level in the body could increase the rate of free radical production in 
the lens to a point at which the normal defenses are overcome and 
damage results.11 
7 
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Free Radicals 
Free radicals are molecules that contain one or more unpaired 
electrons, this makes them highly reactive and very unstable. When 
a free radical reacts with a non-radical compound by stealing an 
electron , other free radicals are formed in a chain reaction that can 
be thousands of events long.13 This chain reaction continues until 
two free radicals react with each other to form a non-radical or 
until the free radical reacts with a molecule · that can donate an 
electron without itself becoming a dangerous free radical. 
Compounds that have the abmty to donate electrons in this manner 
are referred to as free radical scavengers, quenchers, or 
antioxidants . 
Oxygen free radicals are capable of damaging nucleic acids , 
proteins and free amino acids, lipids and lipoproteins, 
carbohydrates, and connective tissue macromolecules.14 This 
damage can affect cellular metabolism, gene expression, and 
membrane function. Membranes are particularly susceptible to free 
radical damage because they are made up primarily of 
polyunsaturated fatty acids that contain a high number of double 
bonds. These double bonds provide a rich source of electrons for 
free radicals to steal, but the theft leaves the membrane severely 
damaged.15 
In the eye, quanta of light react with various molecules to 
form free radicals . When this occurs · in the retina, the result can be 
age-related macular degeneration;16-19 when it occurs in the lens, 
cataracts can resuft.20-23 In support of the theory that cataracts 
are the result of free radical damage, Varma et aJ.24 have found 
8 
higher levels of malondialdehyde, a by-product of free radical 
damage, in lenses with brunescent cataracts. Based on this theory, 
it is possible that the elevated levels of oxygen produced by HBOT 
could accelerate the normal rate of lens damage and cause a rapid 
onset of cataracts and/or myopia. 
Antioxidants 
The body normally uses several defense mechanisms to protect 
itself against free radical damage. One of these mechanisms 
involves the use of enzymatic antioxidants including; superoxide 
dismutase (SOD), catalase, glutathione peroxidase (GSH Px), and 
glutathione reductase (GSSG-R). Specific functions of these 
enzymes are reviewed in Appendix A. 
The body•s other major free radical defense involves the use of 
antioxidant vitamins that have the ability to quench or reduce free 
radicals to relatively non-toxic substances. The primary antioxidant 
vitamins are C, E, and beta carotene. Technically beta carotene is a 
pro-form of vitamin A and not a vitamin, but it is a potent, fat-
soluble antioxidant. Specific functions of the antioxidant vitamins 
are described in Appendix A. 
Evaluation of Defenses Against Free Radicals 
Because free radicals are capable of causing so much damage, 
a biochemical profile has been developed to assess the strength of 
the body's enzymatic defense mechanisms. The free radical enzyme 
scavenging activity (FRESA) profile measures blood concentrations 
of five enzymes and three minerals that are important in free 
radical defense. The specific components of the FRESA profile are 
listed on Table 1. In general, higher levels _ of the enzymes and 
9 
I 
l 
J 
minerals included in the profile indicate more protection against 
free radicals. If it is assumed that HBOT related myopic changes are 
caused by free radical damage, it is possible that subjects with 
lower levels of protection, would be more susceptible to increases 
in myopia. For individuals with low defense levels, it is also 
possible that supplementation with antioxidants could provide 
protection against the visual changes caused by H BOT. 
--------------------------------------~ --- -------------------
Insert Table 1 About Here 
------------------------ ---- - - -------------- -----------------
Project Goals 
The goals of this project were to corroborate previous studies 
in which HBOT was shown to cause increased myopia, to determine 
which structural elements of the eye are responsible for increased 
myopia, to assess biochemical indicators of susceptibility to 
myopia, anq to evaluate the protection provided by antioxidant 
supplements. 
In the project, 6 questions were addressed: 
1. What percentage of subjects receiving 40 hours of HBOT 
would experience significant vision changes? 
2. What biochemical changes are associated with visual 
changes? 
3. Are there any visual or biochemical factors (e.g., FRESA 
profiles) that predict which subjects will experience visual 
changes? 
4. What structural changes in the eyes cause subjects to 
experience visual changes as a result of HBOT? 
1 0 
5. What can be done to protect subjects against visual changes 
caused by HBOT? 
6. Are there any implications of these findings for persons not 
receiving HBOT? 
To address these questions, two project phases were 
conducted. In the first phase, visual acuity and refractive error 
corrections were monitored for four subjects who received at least 
40 hours (20 two hour sessions) of HBOT. In the second phase, visual 
and biochemical data were monitored for four additional HBOT 
subjects. Subjects were provided with antioxidant supplements at 
the midpoint in their HBOT to assess possible protective effects of 
the supplements. 
PHASE 1 - ACUITY AND REFRACTION CHANGES DURING HBOT 
In the first phase of the project, the effects of HBOT on 
refractive error corrections and best corrected acuities were 
measured. 
Subjects 
Four out-patients at Providence Portland Medical Center, 
Portland, OR participated in this phase of the project. Prior to 
HBOT, subjects received a physical examination and signed an 
informed consent form. 
Subjects all had diagnoses of either mandibular osteoradiation 
necrosis or non-healing soft tissue necrosis (Table 2). Those with 
radiation necrosis had been treated for cancer but were considered 
cancer free at the time of the study. Potential subjects with a 
history of diabetes mellitus were excluded due to the possibility of 
diabetic refractive changes. Also excluded were persons taking 
1 1 
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1 antioxidant supplements. An attempt was made to exclude smokers, 
but the small population from which recruiting was done prevented 
this. 
--------------------- ------------- --------------------------~ 
Insert Table 2 About Here 
a •••••••••••••••••••••~••••••••••••••••••••••••••••••••••••• • 
Methods 
Hyperbaric Therapy 
Hyperbaric therapy was provided in several 2 hour sessions per 
week. During each session the subject was placed into a Sechrist 
Model 25008 monoplace hyperbaric chamber. The chamber consisted 
of a 7 foot long clear Plex,iglas tube approximately 30 inches in 
diameter with end caps to allow patient access (Figure 1 ). Each 
treatment involved a 2 hour exposure to 100% oxygen at two 
atmospheres of pressure. Twenty sessions (40 hours) were typically 
prescribed, but one subject received an additional 10 sessions. 
----------- - ------ -- ----- - ------~ ---------- - --------- ----- ---
Insert Figure 1 About Here 
---------- ----- ---------- - -- ---- ----------- ---- -----------~ - -
Vision Testing 
Each subject's vision was tested at the beginning, midpoint, 
and end of the 20 session course of HBOT. For some subjects this 
schedule could not be met exactly, but no subject varied by more 
than 3 sessions from the schedule. 
Vision testing involved a determination of the subject's best 
distance refraction and Snellen acuity measured through her or his 
12 
best correction. Measurements were made by an optometrist with 
10 years of clinical experience. 
Results 
Results are shown on Table 3. Note that only subject number 1 
experienced a significant increase in myopia during HBOT. Note also 
that the best corrected acuities remained normal for all subjects 
including the one who experienced an increase in myopia. This 
suggests that HBOT did not have a significant effect on foveal 
integrity. 
On Table 3, "Begin," •Mid," and "End" refer to measurements 
made at the beginning of therapy, midway through the 20 sessions, 
and near the end. For subject 1, the term "Extra" refers to 
measurements made after an additional 10 sessions of HBOT. 
-- -- ---- - - ------ - ------ ------- - - ----------------- - -- - ------- -
Insert Table 3 About Here 
----------- - -------- ------ ----------- -- ----- --- -- --- ---- - - ---
Besides assessing long term changes in vision over the course 
of HBOT, short term changes produced during single sessions were 
also assessed. This was done by determining refractive error 
corrections and acuities before and after the beginning, midpoint, 
and ending sessions for which long term data were collected. None 
of the subjects, including subject 1, showed any significant effects 
produced by single HBOT sessions. 
PHASE 2 - VISUAL AND BIOCHEMICAL EFFECTS OF HBOT 
In this phase, four additional subjects were followed through 
their course of HBOT. Refractive error corrections and best 
corrected Snellen acuities were determined, and blood samples were 
1 3 
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obtained at the beginning, mid, and ending point& of therapy. The 
blood samples were analyzed for levels of protection against free 
radical damage (FRESA profiles) and for evidence of free radical 
damage. During the second half of this project phase, the ability of 
an antioxidant vitamin and mineral supplement to protect against 
vision changes was assessed. 
Subjects 
Selection criteria for the four subjects were the same as for 
Phase 1. Characteristics are shown on Table 4. 
---- - -------- - - -------------- -- ----------- -- ------~ - -------- -
Insert Table 4 About 
---- -- - ---- . - - -- - ---- -------. ~ ~ --- -------- - - -- ---- -- --- -- -- --
Hyperbaric Therapy 
Hyperbaric therapy was delivered as described in Phase 1. 
Vision and Ocular Testing 
Refractive error and best corrected Snellen acuity data were 
acquired as described in Phase 1, however keratometry 
measurements were added. In addition, A-scan ultrasound 
measurements were obtained at the beginning and end of therapy for 
3 of the 4 subjects (subject number 5 did not wish to have these 
measurements made). 
A-scan measurements were made with a Sonomed model A-
2500 unit. Five measurements of anterior chamber depth, lens 
thickness, and axial length were made for each eye. The highest and 
lowest values were dropped, and the means and ranges of the 3 
remaining measurements were recorded. 
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Free Radical Assays . 
Venous blood was drawn from subjects before and after the 
beginning, midpoint, and ending HBOT sessions Samples were 
prepared by Providence Hospital personnel and sent to the FRESA 
BioMedical Laboratories, Redmond, WA a for analysis. Blood samples 
were coded to mask subject identity. 
FRESA data included levels of 5 antioxidant enzymes .and 3 
minerals which are believed to provide protection against free 
radical damage (Table 1 ). Also measured were malondialdehyde 
(MDA) levels. These levels were of interest because MDA is produced 
when lipid peroxyl free radicals are neutralized by antioxidant 
enzymes. MDA levels, therefore, provide an indirect indicator of the 
degree to which free radical production is occurring.25 
Antioxidant Supplementation 
During the first half of the 20 session course of HBOT, · 
subjects were given inert placebo tablets to take with breakfast and 
dinner. After the midpoint data had been gathered, subjects were 
switched to an antioxidant supplement (ICAPS Plus™).b The 
ingredients in ICAPS Plus are shown in Table 5. Bottles and tablets 
were identical to mask subjects with regard to what product they 
were taking. 
---------- ---- ---- ---------------------- - -- - ----------- - ---- -
Insert Table 5 About Here 
• • • • • • • • • • • • 5 ,~ • • · • -- • • • • • • • • • • • • • • • • • • • • • ~ • • • • • • • • e ~· ~ • • •• • • • • 
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Results 
Vision and Ocular Testing 
Acuity, refractive error, and keratometry data are shown on 
. Table 6. Only subject number 8 showed a significant increase in 
myopia during the course of HBOT. For this subject, keratometer 
readings did not change significantly. This suggests that the 
refractive change was not caused by an alteration in central corneal 
curvature. 
Mean A-scan ultrasound measurements are shown on Table 7. 
These data do not indicate a significant change in anterior chamber 
depth, lens thickness or axial length. 
• - • • - • • • • • • • • - - - - - - - - • • • • • • • • • • - • • • • • • • • ~ - M - 6 ~ • • • • • • • • - - • • • • -
Insert Tables 6 and 7 About Here 
Biochemical Assays 
Results of the FRESA profile and MDA level analyses for the 
before-session blood samples are presented on Table 8. Results 
from the after-session analyses are not presented because they 
were not significantly different from the before-session data. No 
short term effects of single HBOT sessions were found. 
Insert Tahle 8 About Here 
FRESA profiles were designed to predict ·the susceptibility of 
individuals to free radical effects. Note that for the subjects in 
this study, all profile values are within normal limits except for 
GSH Px levels which are low for subjects 5, 6, and 7. Although these 
1 6 
levels could indicate vulnerability to the effects of HBOT, it was 
subject 8, whose profile values were with-in normal limits, that 
experienced the myopic shift. 
Comparing the beginning, midpoint, and ending FRESA profile 
data, there is no indication that any of the levels shifted in a 
consistent and significant manner during the course of HBOT. 
The MDA levels also did not change in a manner that would 
suggest that free radical damage was occurring as a result of HBOT. 
Subject 6 did not show any myopic shift but had higher MDA levels 
than subject 8 who did shift. Also, subject 8's MDA levels did not 
show any increase commensurate with the increase in myopia that 
she experienced. 
In summary, the biochemical assays were not helpful in 
predicting the myopic shift for subject 8 nor in determining its 
cause. 
DISCUSSION 
Percentage of Subjects Experiencing Myopic Shifts 
In previous studies, a high proportion of subjects receiving 
HBOT experienced an increase in myopia. In the present study, 
however, only 2 of 8 subjects showed significant refractive error 
changes. The reason for this disparity probably involves the number 
of HBOT sessions that subjects received. Anderson and Farmer gave 
their subjects 40 sessions (80 hours), and all 7 experienced an 
increase in myopia.9 Palmquist et aJ.11 followed 25 subjects 
through a very large number of sessions and all had myopic shifts. 
Of special interest is the fact that shifts were not noted for 23 of 
their 25 subjects until after they had received at least 100 hours of 
1 7 
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HBOT. This suggests that subjects could have HBOT exposure 
duration thresholds beyond which they would experience increased 
myopia. With 100 hours of exposure, almost all subjects might have 
passed their thresholds. With 40 hours of exposure, however, only 
those with weak antioxidant defenses might experience an increase 
in myopia. 
Etiology of Refractive Changes 
To produce the myopic shift seen in HBOT subjects, a change in 
axial length of the eye, corneal curvature, accommodative tonus, or 
index/curvature of the crystalline lens must have occurred. 
Previous studies have not detected HBOT induced changes in central 
corneal curvature,9,10,12 axial length,10,12 or accommodative 
tonus.1 o Most of these results were confirmed in the present study. 
None of the subjects in phase 2, including the subject who 
experienced an increase in myopia, had significant changes in 
keratometric readings or in axial length of the eye. This suggests 
that lenticular change is the most likely cause of HBOT produced 
myopia. 
Calculations using Gulstrand's schematic eye can be used to 
assess the relative changes in lens parameters required to produce a 
3.00 D myopic shift similar to that experienced by subject 8. With 
respect to lens position, an increase of 3.00 D would require a 2.5 
mm forward displacement.26 Such a displacement would have been 
detectable by A-scan ultrasound, but no such displacement was 
noted in subject 8. 
A change in lenticular thickness could also account for an 
increase in myopia. Based on the work of Patnaik,27 a 3.00 D change 
1 8 
in accommodation causes an approximate 2% increase in the 
thickness of the lens. Assuming a nominal 4.0 mm lens thickness, 
this would result in a thickness change of approximately 0.08 mm. 
Ultrasound data from subject 8 did not show an increase of this 
magnitude, but 0.08 mm is near the accuracy limits of the 
ultrasound unit used in this study. It is possible that an undetected 
increase in lens thickness could have accounted for her myopic shift, 
but it is more likely that the cause was an increase in refractive 
index of the lens. 
An increase of the lens nucleus index from Gulstrand's value of 
1.406 to 1.416 would be needed to create a 3.00 0 increase in 
myopia.26 One possible cause for such an index change could involve 
an alteration in lens proteins. Giblin et aJ.28 demonstrated shifts of 
lenticular water soluble proteins to water insoluble proteins in 
guinea pigs exposed to hyperbaric oxygen. Since the refractive index 
of the lens is a function of its protein concentration,29 this shift 
could theoretically result in an index change without a 
corresponding thickness change. Such an index change would not 
have been detectable with the measurement procedures used in this 
study · except as a change in refractive error. 
Predictive Factors 
Based on the theory that myopic shifts produced by HBOT are 
caused by free radical damage, it was expected that subjects with 
increased myopia would have weak antioxidant defenses and 
abnormal antioxidant enzyme level profiles. This expectation was 
not confirmed. Even though free radical damage can theoretically be 
used to explain increases in myopia, there were no consistent or 
1 9 
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significant differences between the FAESA profiles of subject 8 who 
experienced a myopic shift and those of the subjects who did not. 
It is possible that factors other than those considered in the 
profile account for why some subjects were more prone to damage 
than others. For example, perhaps antioxidants other than the ones 
included in the profile (e.g., vitamins C or E) are important in 
protecting the lens, and subjects who experienced changes may have 
had low levels of these antioxidants. Additionally, it is not certain 
that blood levels of antioxidant enzymes are good indicators of 
levels in the lens itself. 
Protection 
If free radicals produce lenticular damage, is it possible to 
protect subjects against this damage by increasing their antioxidant 
levels? Data from subject 8 do not support a positive answer to 
this question. When subject 8 was taking placebos during the first 
half of HBOT she experienced a spherical equivalent increase of 
approximately -1.00 D in each eye. While taking supplements, the 
increase was greater: -1.75 D OD and -1.25 D OS. 
Although protective effects of antioxidant supplementation for 
HBOT patients were not demonstrated in this study, it is possible 
that the damage had already been done by the time supplements were 
started. It is also possible that the myopic shift during the second 
half of therapy would have been greater without the supplements. 
20 
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Extrapolation of Results 
When the study began, it was considered possible that HBOT 
could be used to demonstrate the damaging effects of free radicals 
on the eyes and evaluate the protective effects of antioxidant 
supplements. In essence, it was considered possible that subjects 
receiving HBOT would undergo the same age-related degenerative 
changes that normal persons experience but in an accelerated 
fashion. This would have provided an ideal way to evaluate the 
effects of antioxidant supplements without having to wait for 
several decades while nature and the aging process took their toll. 
Unfortunately, the effects of 20 HBOT treatments on subjects 
in this study were not consistent. Only 2 subjects showed a myopic 
shift, perhaps because the exposure thresholds for the other 
subjects had not been reached. No physical or biochemical 
correlates of the shift could be found, perhaps because no 
satisfactory means of measuring lens index was used. Never-the-
less, the theoretical support for the free radical theory of lenticular 
damage associated with HBOT remains compelling enough to 
encourage further research on this topic. 
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FOOTNOTES 
a. FRESA profiles and MDA levels were provided by FRESA BioMedical 
Laboratories, Inc. Redmond WA. 
b. ICAPS Plus, LaHaye Laboratories, Redmond, WA. 
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Appendix A - Enzymatic and Vitamin Antioxidants 
Superoxide Dismutase (SOD) 
Superoxide dismutase is a major enzyme involved in combating 
free radicals, it neutralizes the superoxide radical by accelerating 
its conversion to hydrogen peroxide. SOD comes in several forms 
including a manganese form (MnSOD) that exists in the mitochondrial 
matrix, and a copper/zinc form (CuZnSOD) that is present largely in 
the cytoplasm.30 Although hydrogen peroxide is less damaging to 
the body than is the superoxide radical, it can still damage certain 
cellular components and interfere with cellular metabolism if its 
concentration becomes too great.31 Because the action of SOD 
results in the production of hydrogen peroxide, SOD works in 
collaboration with a hydrogen peroxide removing enzyme called 
catalase. 
Catalase 
Catalase functions by converting hydrogen peroxide to water 
and oxygen. Because the ·concentration of catalase is 1,000 times 
higher than that of any other free radical scavenging enzyme, it can 
be considered to be the first line of defense against hydrogen 
peroxide.32 It is thought that a large concentration of catalase in 
the body is needed to prevent the decomposition of hydrogen 
peroxide to hydroxyl radicals which readily react with lipid 
membranes and damage them. 
Glutathione Peroxidase (GSH Px) 
The body's second line of defense against hydrogen peroxide 
involves the use of glutathione peroxidase which is a selenium 
containing protein. When catalyzed by the glutathione peroxidase 
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I enzyme, reduced glutathione (GSH) reacts with hydrogen peroxide to 
form oxidized glutathione (GSSG) and water. The most important 
property of GSH-Px, however, is its ability to convert lipid 
peroxides formed during free radical mediated lipid peroxidation to 
non-radical alcohols. 
Glutathione Reductase (GSSG-R) 
Glutathione reductase is responsible for the conversion of 
oxidized glutathione to the reduced form. An insufficiency of GSSG-
R can lead to an inadequate supply of reduced glutathione. This will 
limit glutathione peroxidase's activity, thereby diminishing the 
body's defense against lipid peroxidation. 
Vitamin C. 
Vitamin C, also know as ascorbic acid, is a water soluble 
compound that functions as a reducing agent. When combined with 
oxygen, ascorbic acid forms dehydroascorbate and hydrogen peroxide. 
The hydrogen peroxide is then converted to water by the enzymatic 
reactions previously described. 
The concentration of ascorbic acid in the human aqueous is 15 
to 20 times higher than in the blood plasma.33 This is important 
because it has been suggested that ascorbic acid prevents the 
oxidation of protein sulfhydryl groups in the lens cortex.34 Lenses 
incubated with ascorbic acid were found to be protected against 
photocatalytic deterioration and photoperoxidation, two elements 
linked to cataract formation.2 4 
Beta Carotene 
Beta carotene is a carotenoid pigment found in many fruits and 
vegetables. Carotenoids are know to be good quenchers of free 
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radicals, and beta carotene is one of the best. It is highly reactive 
with peroxyl radicals which makes it useful for reducing the 
concentration of certain lipid peroxyl radicals.35 
Vitamin E (Alpha-Tocopherol) 
Alpha-tocopherol (vitamin E) is the most biologically active of 
the naturally occurring tocopherols.36 It is a fat soluble antioxidant 
that is the body's most important free radical scavenger within 
membranes and lipoproteins.37 Alpha-tocopherol inhibits lipid 
peroxidation by scavenging lipid peroxyl radicals. In this process, 
the alpha-tocopherol molecule becomes a free radical itself. 
However, it is significantly less reactive than the peroxyl radical 
and is much less harmful to the body. 
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TABLE 1 - FRESA PROFILE COMPONENTS 
PRO ALE COMPONENT 
Glutathione Peroxidase (GSH-Px) 
Glutathione-S- Transferase (GST) 
Glutathione Reductase (GSSG-R) 
Catalase 
Superoxide dismutase (SOD) 
Selenium (Se) 
Copper (Cu) 
Zinc (Zn) 
BIOCHEMICAL FUNCTION 
Converts lipid peroxide free radicals 
formed during lipid peroxidation to non-
toxic alcohols. Helps to maintain cell 
membrane integrity. Also augments 
catalase to convert hydrogen peroxide to 
water and oxygen. Requires selenium. 
·Metabolizes lipid peroxides. 
Converts oxidized glutathione to reduced 
glutathione. Acts as a cofactor for 
glutathione peroxidase activity. 
Insufficiency will lead to decreased GSH-
Px activity. Zinc dependent. 
Converts hydrogen peroxide to water and 
oxygen. 
Zinc and copper dependent. 
Converts superoxide radical to hydrogen 
peroxide. Zinc, copper, and manganese 
dependent. 
Required for glutathione peroxidase 
synthesis. 
Required for synthesis of superoxide 
dismutase. 
Required for synthesis of superoxide 
dismutase and catalase. 
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l TABLE 2 - CHARACTERISTICS OF SUBJECTS IN PHASE 1 
Subject 
Number ~ S.U Smoker Diagnosis Medications 
51 F 
2 38 F 
3 37 M 
4 65 M 
y 
N 
y 
N 
Mandibular radiation Clindamycin 
necrosis 
Non-healing skin 
lesion of leg 
Mandibular radiation 
necrosis 
Zantac, Proventil, 
AeroBid, 
Erythromycin, 
Dyazide 
None 
Radiation soft tissue lnderal, lsosorbide, 
necrosis of rectum Aspirin 
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TABLE 3- RESULTS OF VISION EVALUATIONS FOR PHASE 1 SUBJECTS 
QQ ~ 
Best VA Refractjon Best VA Refractjon 
SUBJECT 1 
Begin 20/15 -1.25 -1.00x90 2 0/1 5 -1.00 -0.75x80 
Mid 20/20 -2.25 -0.75x90 20/15-1 -1.75 -0.75x75 
End 20/20 -3.25 -0.50x90 20/20 -2.25 -0.75 x75 
Extra 20/20 -3.50 -0.50x85 20/20 -2.50 -0.75x70 
SUBJECT 2 
Begin 20/1 5 +0.50 -0.25x70 2 0/1 5 +0.25 Sphere 
Mid 2 0/1 5 +0.25 -0.25x90 2 0/1 5 PL Sphere 
End 20/1 5 +0.25 Sphere 2 0/1 5 PL Sphere 
SUBJECT 3 
Begin 2 0/1 5 -1.00 Sphere 2 0/1 5 -0.50 -0.50x45 
Mid 20/15-2 -1.25 Sphere 20/15-2 ·0.75 -0.50x40 
End 20/15-2 -1.25 Sphere 2 0/1 5 -0.75 ·0.50x45 
SUBJECT 4 
Begin 20/1 5 +0.75 -0.50x120 2 0/1 5 +0.75 -0.75x80 
Mid 2 0/1 5 +0.75 ·0.75x130 2 0/1 5 +0.50 -0.50x1 00 
I End 2 0/1 5 +0.50 -0.75x130 2 0/, 5 +0.25 -0.75x95 
j 
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TABLE 4- CHARACTERISTICS OF SUBJECTS IN PHASE 2 
Subject 
Number A® ~ Smoker Diagnosis Medications 
5 31 F 
6 63 M 
7 68 F 
8 53 F 
N 
N 
N 
y 
Mandibular radiation None 
necrosis 
Mandibular radiation Unknown antibiotic 
necrosis 
Soft tissue radiation Valium, Sudafed, 
necrosis of colon Lomotil , Estrogen 
Radiation soft tissue Unknown antibiotic, 
necrosis of larynx Valium, Advil, Cough 
syrup, Antacids 
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Table 5- INGREDIENTS IN ICAPS Plus™ 
(VALUES IN PARENTHESES ARE PERCENTAGES OF ADULT ADA) 
Vitamin A (as Beta Carotene) 
Vitamin C (Ascorbic Acid) 
Vitamin E (di-Aipha Tocopheryl Acetate) 
Riboflavin (Vitamin 8-2) 
Zinc (Zinc Acetate) 
Cooper 
Manganese 
Selenium (1-Selenomethionine) 
* U.S. RQA not established. 
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6000 I.U .. (120%) 
200 mg. (330%) 
60 I.U. (200%) 
20 mg. (1180%) 
40 mg. (260%) 
2 mg. (100%) 
5 mg. * 
20 meg. * 
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TABLE 7 - MEAN ULTRASOUND MEASUREMENTS FOR PHASE 2 SUBJECTS 
(MEANS ARE IN MILLIMETERS; VALUES IN PARENTHESES ARE RANGES 
OF 3 MEASUREMENTS) 
Anterior Anterior 
Chamber Lens Chamber Lens 
.QgQ1h Thickness Axial Length Depth Thickness Axial Length 
SUBJECT 6 
Begin 3.74 (0.08) 4.54 (0 .08) 23.17 (0.06) 3.81 (0.00) 4.62 (0 .04) 23.10 (0 .04) 
End 3.81 (0.07) 4.53 (0 .08) 23. 15 (0.00) 3.88 (0.04) 4.52 (0.04) 23.14 (0.04) 
SUBJECT 7 
Begin 3.52 (0.00) 4.64 (0.04) 24.81 (0.03) 3.42 (0.03) 4.70 (0 .04) 24.61 (0.08) 
End 3.47 (0.04) 4.66 (0 .04) 24.77 (0.04) 3.40 (0 .04) 4.69 (0.00) 24.57 (0.08) 
SUBJECT 8 
Begin 3.15 (0.00) 4.54 (0 .08) 23.21 (0.04) 3.15 (0.00) 4.66 (0.08) 23.36 (0.04) 
End 3.16 (0.03) 4.49 (0.00) 23.26 (0.00) 3.07 (0.07) 4.66 (0.04) 23.33 (0.00) 
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TABLE 8- RESULTS OF FRESA AND MDA BLOOD ANALYSES 
(VALUES SHOWN BELOW EACH COMPONENT ARE NORMAL RANGES) 
GSHPx GSf GSSGR Catalase SOD Se Q.j Zn MDA 
30.3-44.1 0.8-2.4 5.4-8.8 16,500-26,500 6 ,500-14,500 100· 200 0.75-1.45 0.65·2 .00 1.0-2.0 
~ l.UlG. lWi .!..!&.HS UlGJ:IB n.gLmJ. yglm1 yglm1 NMQL 
SUBJECTS 
Begin 20.9 2 .. 5 6.0 22,922 9,675 115 0.92 0 .82 1.2 
Mid 19.3 2.2 5.5 19,786 12,608 133 0.89 1.12 0.9 
End 21.0 2.5 5.6 22,698 10,898 114 1.07 0.86 1.4 
SUBJECTS 
Begin 25 .1 2.5 7.0 19,656 13,307 92 1.16 1.97 2.2 
Mid 27.5 2.0 7.0 19,026 12,966 126 0.98 1.85 2.2 
End 25.1 2.7 6.6 18,506 11,390 123 1.04 0.94 2.2 
SUBJECT7 
Begin 29.6 3 .2 6 .9 24,890 10,099 121 1 .15 0 .82 1.8 
Mid 27.2 3.0 7.4 24,993 13,770 121 1.12 1.32 1.5 
End 22.0 2.0 7.8 19,262 11,581 128 1.24 1.75 1.6 
SUBJECTS 
Begin 32.8 3.1 6.4 26,203 10,802 154 0.94 1.31 2.0 
Mid 32.5 3.5 5.8 26,976 10,901 155 0 .95 0 .93 2.0 
End 32.5 2.8 7.9 25,818 13,774 147 0.76 1.32 1.7 
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Figure Captions 
Figure 1. The Sechrist Model 25008 monoplace hyperbaric chamber. 
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